CORDIS
EU research results

CORDIS

English EN

Targeting Cartilage Regeneration in joint and intervertebral disc diseases

Objective

Mobility, important for well-being, is seriously impaired by chronic low back pain and osteoarthritis in many people due to degeneration of cartilaginous tissue of the intervertebral disc and joint. To develop a treatment for these diseases this ETN aims to combine expertise in novel highly advanced drug delivery carriers with dedicated targeting tools, state of the art imaging techniques and expertise in stem cell and joint biology by training 15 young scientists in 12 partner institutes located in 5 different countries.
We aim to achieve regeneration of damaged and degenerated tissues by employing targeting strategies tailored both to the pathology and the tissues involved. Regeneration of diseased tissues will be achieved by loading biologically active agents in state-of-the-art nanocarriers. The biologically active agents will stimulate the body’s own capacity to regenerate by attracting local stem cells or inhibit degeneration. Targeting will be achieved by A] injection with synthetic or natural hydrogels loaded with the nanocarriers or B] coupling diseased tissue-specific antibodies and specific hyaluronic acid moieties to the nanocarriers. Delivery and retention will be monitored by advanced in vivo and molecular imaging techniques to monitor distribution of the delivered compounds at the tissue level, as well as detect biological markers of regeneration.

Major objectives:
1] To establish a network of scientists skilled in the use of smart nanocarriers, unique approach of targeting by disease-specific molecules and application of innovative imaging tools. Supported by generic scientific and training in economical and clinical valorisation, these researchers can further implement these technologies in the musculoskeletal or other areas, both in academia and industry.
2] To develop strategies exclusively targeting diseased tissues with controlled doses of bio-actives, circumventing the disadvantages of the current shotgun approaches in regenerative medicine.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 Gd Rotterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 510 748,56

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 546 575,76

PERCUROS BV

Netherlands

EU Contribution

€ 255 374,28

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

EU Contribution

€ 273 287,88

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 520 601,04

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 255 374,28

AO-FORSCHUNGSINSTITUT DAVOS

Switzerland

EU Contribution

€ 530 453,52

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 290 081,88

PROCORE LTD

Israel

EU Contribution

€ 260 300,52

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 255 374,28

Partners (2)

Sort alphabetically

Expand all

Omics2Image

STICHTING NATIONAAL REUMAFONDS

Project information

Grant agreement ID: 642414

Status

Closed project

  • Start date

    1 March 2015

  • End date

    28 February 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 971 459,88

  • EU contribution

    € 3 971 459,88

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands